rs1050565(C;C)

If testicular cancer patient, 5x poorer response to bleomycin chemotherapy

Magnitude
2.0Worth knowing
Repute
Bad
Frequency
6%Average of 11 populations
On SNPedia
rs1050565(G;G)Minus strand
Gene
BLMH

Frequency

Share of people with C;C in each HapMap population.

  • Maasai (Kenya)12%
  • Luhya (Kenya)12%
  • Japanese (Tokyo)9%
  • Mexican ancestry (Los Angeles)9%
  • European ancestry (Utah)8%
  • Gujarati Indian5%
  • Tuscan5%
  • Yoruba (Nigeria)4%
  • Han Chinese (Beijing)3%
  • African ancestry (Southwest US)2%
  • Chinese (Denver)2%

Other genotypes of rs1050565

  1. T;TGoodnormalTypical · 0.060% of people
  2. C;TNot ratednormalTypical · 0.034% of people

All about rs1050565

Notes

From SNPedia

Testicular cancer patients may be treated with bleomycin, a cytotoxic drug that is essential component of chemotherapy regimens for this cancer, officially known as disseminated testicular germ-cell cancer (TC). rs1050565 is a SNP in the BLMH gene. This gene encodes a protein that can inactivate bleomycin. Based on a study of 300 TC patients treated with bleomycin, a testicular cancer patient with a rs1050565(G;G) genotype has an odds ratio of 4.97 (CI: 2.17 - 11.39) for TC-related death compared to (A;G) or (A;A) genotypes. The rs1050565(G;G) genotype also shows a higher prevalence of early relapses. Note that this gene affects bleomycin metabolism; the GG does not mean that a person is more likely to get testicular cancer.

Source and license

Adapted from rs1050565(G;G) on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.